爱游戏ayx(中国)官方网站,爱游戏app官方网站

您好,欢迎光临爱游戏ayx(中国)官方网站商城!
服务热线:400 680 0892
新闻资讯 News

BioXCell——助力体内临床前研究

2022-05-11
浏览次数: 464

BioXCell的中和/阻断抗体受到国内外研究者的普遍热爱和青睐,在肿瘤、癌症等方面的研究中广受好评。BioXCell公司位于美国新罕布什尔州,具有25年以上单克隆抗体和重组蛋白的生产及定制经验,可提供高纯度、低内毒素、无防腐剂、适用于体内临床前研究的单克隆抗体。


BioXCell——助力体内临床前研究高纯度、低内毒素,无防腐剂,适用于体内临床前研究
超过二十五年单克隆抗体和重组蛋白生产及定制经验
性价比高,可提供100mg甚至50g的大包装
超过15000篇高质量期刊文献引用


肿瘤癌症免疫治疗应用 

抑制免疫检查点和其他免疫调节来治疗恶性肿瘤是现在利用免疫系统杀死肿瘤细胞的有力途径。BioXCell提供三种不同克隆号的anti mouse PD-1抗体:RMP1-14、29F.1A12和J43。三种抗体都通过相同的机制发挥作用—它们结合PD-1,并在空间上阻断PD-1与PD-1配体的结合,从而阻断PD-1信号传导。这三种克隆号的抗体都非常适合在小鼠体内模型中阻断PD-1信号传导,并有大量文献支持这一应用。这些抗体之间的差异在于文献报道中的其他应用、Isotype和来源。

通过用阻断PD-L1和它的受体PD-1之间的相互作用的抗体治疗,肿瘤生长可以暂时被抑制。

抗PD-1联合抗CTLA-4抗体介导的免疫治疗对黑色素瘤、肾细胞癌和非小细胞肺癌具有显著疗效。

通过靶向调节免疫反应的途径,如RANK途径,可以将“cold”肿瘤转化为“hot”肿瘤。使用Bio X Cell’s Anti-mouse RANKL (clone IK22/5) antibody,研究人员证明了对RANK通路的抑制将“cold”乳腺肿瘤转化为“hot”肿瘤,变为“hot”的肿瘤可能受益于免疫疗法。



肿瘤研究相关的抗体

抗体指标应用克隆号InVivoMabInVivoPlus同型对照稀释液
Anti mouse PD-1(CD279)In vivo blocking of PD-1/PD-L signalingRMP1-14BE0146BP0146BE0089IP0070
In vivo blocking of PD-1/PD-L signaling
In vitro PD-1 neutralization
IHC-Fr/Immunofluorescence/WB/FC
29F.1A12BE0273BP0273BE0089IP0070
In vivo blocking of PD-1/PD-L signaling
In vitro PD-1 neutralization
WB
J43BE0033-2BP0033-2BE0091IP0065
Anti mouse PD-L1(B7-H1)In vivo PD-L1 blockade
IHC-Fr/Immunofluorescence/WB/FC
10F.9G2BE0101BP0101BE0090IP0065
Anti mouse CTLA-4 (CD152)In vivo CTLA-4 neutralization
WB
9D9BE0164BP0164BE0086IP0070
In vivo CTLA-4 neutralization
In vitro CTLA-4 neutralization
WB
9H10BE0131BP0131BE0087IP0070
In vivo CTLA-4 neutralization
In vitro CTLA-4 neutralization
WB/FC
UC10-4F10-11BE0032BP0032BE0091IP0065
Anti mouse CD4In vivo CD4+ T cell depletion
WB/FC
GK1.5BE0003-1BP0003-1BE0090IP0065
Anti mouse CD8αIn vivo CD8+ T cell depletion
Immunofluorescence/WB/FC
53-6.7BE0004-1BP0004-1BE0089IP0065
In vivo CD8+ T cell depletion
WB
2.43BE0061BP0061BE0090IP0070
In vivo CD8+ T cell depletion
WB
YTS 169.4BE0117BP0117BE0090IP0070
Anti mouse Ly6GIn vivo neutrophil depletion
In vivo MDSC depletion
IHC-P/IHC-Fr/IF/FC
1A8BE0075-1BP0075-1BE0089IP0065
Anti mouse Ly6G/Ly6C (Gr-1)In vivo depletion of Gr-1+ myeloid cells
IHC-P/IHC-Fr/FC
RB6-8C5BE0075BP0075BE0090IP0070
Anti mouse IFNγIn vivo IFN-γ neutralization
In vitro IFN-γ neutralization
ELISPOT/WB/FC
XMG1.2BE0055BP0055BE0088IPT080
Anti mouse IFNAR-1In vivo IFNAR-1 blockade
In vitro IFNAR-1 blockade
WB
MAR1-5A3BE0241BP0241BE0083IP0070

Anti-mouse/human/rat/monkey/hamster/

canine/bovine TGF-β

In vivo TGF-β neutralization
In vitro TGF-β neutralization
WB
1D11.16.8BE0057BP0057BE0083IP0070
Anti mouse CD28In vitro T cell stimulation/activation
In vivo CD28 blockade
37.51BE0015-1/BE0087IPT060
in vitro T cell stimulation/activationPV-1BE0015-5/BE0091IP0070
Anti mouse CD3εIn vitro T cell stimulation/activation
In vivo T cell depletion
Immunofluorescence/WB/FC
145-2C11BE0001-1BP0001-1BE0091IP0070
Anti-human CD3In vitro T cell stimulation/activation
In vivo T cell depletion in humanized mice
Ex vivo T cell inhibition for xenografts
FC
OKT-3BE0001-2/BE0085IP0070
Anti mouse CD40In vivo CD40 activation
In vitro B cell stimulation/activation
FGK4.5/ FGK45BE0016-2BP0016-2BE0089IP0070
Anti mouse CD154 (CD40L)In vivo blocking of CD40/CD40L signaling
In vitro blocking of CD40/CD40L signaling
WB
MR-1BE0017-1BP0017-1BE0091IP0070
Anti mouse CD25 (IL-2Rα)In vivo regulatory T cell depletion
FC
PC-61.5.3BE0012BP0012BE0088IP0070
Anti mouse IL-4In vivo IL-4 neutralization
In vitro IL-4 neutralization
In vivo IL-4 receptor stimulation (as a complex with IL-4)
FC/WB
11B11BE0045BP0045BE0088IP0070
Anti mouse NK1.1In vivo NK cell depletion
FC
PK136BE0036BP0036BE0085IP0070
Anti mouse CSF1R (CD115)In vivo macrophage depletion
In vitro CSF1R neutralization
In vivo monocyte depletion
FC/WB
AFS98BE0213BP0213BE0089IP0070
Anti mouse CD25 (IL-2Rα)In vivo regulatory T cell depletion
FC
PC-61.5.3BE0012BP0012BE0088IP0070
anti-mouse OX40 (CD134)In vivo OX40 activation
In vitro OX40 activation
WB
OX-86BE0031BP0031BE0088IP0070


畅销同型对照抗体


同型对照InVivoMabInVivoPlus

目录号目录号
Rat IgG2a Isotype control, FCBE0089BP0089
Rat IgG2b Isotype controlBE0090BP0090
Mouse IgG1 Isotype controlBE0083BP0083
Rat IgG1 Isotype controlBE0088BP0088
Mouse IgG2a Isotype controlBE0085BP0085
Mouse IgG2b Isotype controlBE0086BP0086
Polyclonal Armenian Hamster IgGBE0091BP0091



InVivoPlus™ Vs InVivoMab™系列之间区别


InVivoMabInVivoPlus
纯度> 95%> 95%
蛋白完整性√ (verified via SDS-PAGE)√ü(verified via SDS-PAGE)
内毒素浓度< 2EU/mg< 1EU/mg
不含叠氮化物和载体蛋白
是否适用于体内研究
是否提供大包装
是否经WB, FC或ELISA验证
经验证蛋白聚集≤ 5%
是否经过鼠科病原体检测
产品货号BE-开头BP-开头


BioXCell的RecombiMAb系列抗体

BioXCell的RecombiMAb系列抗体是新开发的重组单克隆抗体,具有与其传统克隆号来源相同的抗原结合可变区,但IgG恒定区已从大鼠或仓鼠IgG变为小鼠或人IgG。这意味着对于小鼠模型或人源化小鼠模型的免疫原性降低。


RecombiMAb单克隆抗体

产品名称宿主亚型货号同型对照稀释液应用
Anti-Mouse PD-1 (CD279) (D265A)MouseIgG2a, ΚCP151CP150IP0070in vivo blocking of PD-1/PD-L signaling
Anti-Mouse CTLA-4 (CD152)MouseIgG1, ΚCP146BP0083IP0070In vivo CTLA-4 neutralization 
In vitro CTLA-4 neutralization 
WB
Human IgG4 (S228P) Isotype Control, Anti-Hen Egg LysozymeHumanIgG4, ΚCP147---
Human IgG4 S228P L235E P329G (SPLEPG) Isotype Control, Anti-Hen Egg LysozymeHumanIgG4CP148---
Human IgG1 (LALA-PG) Isotype Control, Anti-Hen Egg LysozymeHumanIgG1CP149---
Mouse IgG2a (D265A) Isotype Control, Anti-Hen Egg LysozymeMouseIgG2aCP150---

BioXCell的重组融合蛋白

融合蛋白即通过将细胞表面受体的结合域与抗体的Fc部分结合而形成,这样可以使得配体分子不会结合到内源性受体,从而阻断受体信号的传导。蛋白纯度大于95%,内毒素水平超低,不含防腐剂、稳定剂和载体蛋白等试剂,专为体内研究而开发。

货号产品名称货号产品名称规格
BE0099InVivoMAb recombinant CTLA-4-lgBP0099InVivoPlus recombinant CTLA-4-Ig5mg,25mg,50mg,100mg
BE0098InVivoMAb recombinant Flt-3L-lgBE0148InVivoMAb recombinant Mouse Angiosestatin-lg5mg,25mg,50mg,100mg
BE0149InVivoMAb recombinant Mouse Endostatin-lg--5mg,25mg,50mg,100mg


产品图片:

BioXCell——助力体内临床前研究



更多详情请咨询 Bioxcell一级代理商-欣博盛生物    

全国服务热线: 4006-800-892  邮箱: market@hnyazd.com  

深圳: 0755-26755892      北京: 010-88594029      上海: 021-34613729            

广州:020-87615159      香港: 852-69410778  

代理品牌网站: www.hnyazd.com  

自主品牌网站: www.neobiosescience.net

分享到:
关注欣博盛公众号
Copyright ©2021 - 2023 深圳爱游戏ayx(中国)官方网站有限公司
  网站地图
犀牛云提供企业云服务
爱游戏ayx(中国)官方网站